Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone303-625-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$95.39 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/29/2019 (Estimated)
OptionableOptionable
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) posted its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($2.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.70) by $0.57. The biopharmaceutical company earned $32.98 million during the quarter, compared to analyst estimates of $34.92 million. Clovis Oncology had a negative net margin of 332.18% and a negative return on equity of 372.68%. The firm's revenue was up 38.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.94) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What guidance has Clovis Oncology issued on next quarter's earnings?
Clovis Oncology issued an update on its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $137-147 million, compared to the consensus revenue estimate of $145.81 million.
What price target have analysts set for CLVS?
14 Wall Street analysts have issued twelve-month price targets for Clovis Oncology's stock. Their forecasts range from $7.00 to $36.00. On average, they expect Clovis Oncology's stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 332.9% from the stock's current price. View Analyst Price Targets for Clovis Oncology.
What is the consensus analysts' recommendation for Clovis Oncology?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019)
- 2. According to Zacks Investment Research, "Clovis reported encouraging first-quarter results wherein its earnings and sales beat estimates. Market share of Clovis’ sole marketed drug Rubraca in the ovarian cancer PARP inhibitor market improved during the first quarter. Approval in second-line maintenance setting for ovarian cancer irrespective of BRCA-mutation is a positive. Successful development of Rubraca in several ongoing studies targeting different types of ovarian cancer patients is likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several PARP inhibitors under development. Clovis’ shares have outperformed the industry so far this year." (5/13/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Clovis’ 4Q report was as expected following the top-line pre-announcement at The J.P. Morgan Healthcare Conference. Importantly, all key Rubraca clinical trials remain on track with the next material data updates likely at ESMO in September. In the meantime, we expect investors to continue to focus on the strategic value of the company, particularly in the wake of the GSK/TSRO deal. We are also increasingly asked about CLVS’s cash outlook given an accelerating operating spend and a first round of converts due in 2021 (~$284M). While these questions are likely to persist, we anticipate they will be secondary to the company’s strategic potential." (2/27/2019)
Has Clovis Oncology been receiving favorable news coverage?
Headlines about CLVS stock have been trending positive this week, according to InfoTrie. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Clovis Oncology earned a news impact score of 2.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Clovis Oncology.
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Phibro Animal Health (PAHC), Aimmune Therapeutics (AIMT), Opko Health (OPK), Epizyme (EPZM), Athenex (ATNX), Theravance Biopharma (TBPH), BELLUS Health (BLUSF), Innoviva (INVA), Gossamer Bio (GOSS), Radius Health (RDUS), Odonate Therapeutics (ODT), ArQule (ARQL), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH) and Stoke Therapeutics (STOK).
What other stocks do shareholders of Clovis Oncology own?
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.38%), Orbimed Advisors LLC (3.50%), Candriam Luxembourg S.C.A. (2.09%), Sector Gamma AS (0.81%), Balyasny Asset Management LLC (0.72%) and Nuveen Asset Management LLC (0.68%). Company insiders that own Clovis Oncology stock include Daniel W Muehl, Gillian C Ivers-Read, James C Blair, Lindsey Rolfe, Patrick J Mahaffy, Paul Edward Gross and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which institutional investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Orbimed Advisors LLC, Vanguard Group Inc., Parametric Portfolio Associates LLC, Balyasny Asset Management LLC, Rice Hall James & Associates LLC, Wealthstreet Investment Advisors LLC and Swiss National Bank. Company insiders that have sold Clovis Oncology company stock in the last year include Daniel W Muehl, James C Blair, Lindsey Rolfe and Paul Edward Gross. View Insider Buying and Selling for Clovis Oncology.
Which institutional investors are buying Clovis Oncology stock?
CLVS stock was bought by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Candriam Luxembourg S.C.A., Gamco Investors INC. ET AL, Renaissance Technologies LLC, Gabelli Funds LLC, Virtus ETF Advisers LLC, Fisher Asset Management LLC and Sofinnova Investments Inc.. Company insiders that have bought Clovis Oncology stock in the last two years include James C Blair, Patrick J Mahaffy and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $5.89.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $321.93 million and generates $95.39 million in revenue each year. The biopharmaceutical company earns $-368,010,000.00 in net income (profit) each year or ($7.07) on an earnings per share basis. View Additional Information About Clovis Oncology.
What is Clovis Oncology's official website?
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
